GSK in talks to acquire Nuvalent for more than $9 billion in biggest deal in over a decade: FT
CNBC
—
The deal comes at a time of biotech dealmaking frenzy, driven by looming patent cliffs, newly buoyant public markets and drugmakers' race to bolster pipelines.
GSK Acquires Nuvalent for $10.6 Billion
- GSK just announced its biggest purchase in eight years to rev up cancer portfolio it had previously wound down MarketWatch —
- GSK to buy US cancer treatment firm Nuvalent for $10.6bn The Guardian —
- GSK to buy US lung cancer drug specialist Nuvalent for £8bn The Argus —
- GSK to buy US lung cancer drug specialist Nuvalent for £8bn The Standard —
- GSK agrees to buy US cancer drug firm Nuvalent in £8bn deal Yorkshire Post —